The drug Cytokinetics is placing its hopes on is aficamten, a selective small-molecule inhibitor of cardiac myosin. The drug ...

View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

in obstructive hypertrophic cardiomyopathy (HCM), Cytokinetics submitted an NDA for aficamten to the U.S. Food & Drug Administration and is progressing regulatory submissions for aficamten for the ...

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights.

The exhibition on water supply and drainage, sanitation, water resources and purification technology (Vietwater 2024) and the ...

in obstructive hypertrophic cardiomyopathy (HCM), Cytokinetics submitted an NDA for aficamten to the U.S. Food & Drug Administration and is progressing regulatory submissions for aficamten for the ...

Camzyos is currently the only FDA-approved treatment for HCM and at launch was tipped as a future blockbuster, although its growth has been pegged back by a somewhat onerous risk evaluation and ...

On average, Camzyos treatment reduced LVEF by around 4% from a mean starting level of 74% in EXPLORER-HCM, said BMS, which has developed a risk evaluation and mitigation strategy (REMS ...

Death is a daunting prospect for many, but after a lot of reflection and work on herself, Bella Salsberry feels at peace with the life she's been granted.

Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 Trial of TN-201 Gene ...